<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004497</url>
  </required_header>
  <id_info>
    <org_study_id>199/14287</org_study_id>
    <secondary_id>UTC-FDR001545</secondary_id>
    <secondary_id>UTC-P01-04</secondary_id>
    <nct_id>NCT00004497</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and efficacy of UT-15 in patients with severe symptomatic primary&#xD;
      pulmonary hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.&#xD;
      Patients are stratified according to center and etiology of disease.&#xD;
&#xD;
      Patients receive conventional oral therapy plus a continuous subcutaneous infusion of either&#xD;
      UT-15 or placebo for 12 weeks.&#xD;
&#xD;
      After completing 12 weeks of treatment, patients may continue therapy with open label UT-15.&#xD;
      Patients who received placebo cross over to receive UT-15.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date>September 2000</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UT-15</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of moderate to severe precapillary pulmonary hypertension (New York Heart&#xD;
        Association class III/IV) unresponsive to attempted use of chronic oral vasodilators for at&#xD;
        least 1 month&#xD;
&#xD;
        Cardiac catheterization at baseline: Pulmonary artery pressure at least 25 mm Hg AND&#xD;
        Pulmonary capillary wedge pressure or left ventricular end diastolic pressure no greater&#xD;
        than 15 mm Hg AND Pulmonary vascular resistance greater than 3 mm Hg/L/min&#xD;
&#xD;
        Echocardiogram at baseline: Right ventricular hypertrophy or dilation AND Normal left&#xD;
        ventricular function AND Absence of mitral valve stenosis&#xD;
&#xD;
        Chest radiograph within prior 3 months Clear lung fields OR Multiple patchy interstitial&#xD;
        (not diffuse) lung fields AND At least 1 of the following:&#xD;
&#xD;
          -  Right ventricular enlargement&#xD;
&#xD;
          -  Prominence of main pulmonary artery&#xD;
&#xD;
          -  Enlarged hilar vessels&#xD;
&#xD;
          -  Decreased peripheral vessels&#xD;
&#xD;
        No significant parenchymal lung disease within prior 3 months as evidenced by: Total lung&#xD;
        capacity no greater than 70% predicted FEV/FVC ratio no greater than 50% Diffuse&#xD;
        interstitial fibrosis or alveolitis by high resolution CT if total lung capacity is 70-80%&#xD;
        or DLCO less than 60%&#xD;
&#xD;
        No chronic thromboembolic disease with clot proximal to lobar bifurcation&#xD;
&#xD;
        Baseline exercise capacity at least 50 meters walked in six minutes&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 30 days since prior chronic prostaglandin or prostaglandin analogue therapy&#xD;
             (including Flolan IV)&#xD;
&#xD;
          -  No concurrent prostaglandins or prostaglandin analogues&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 month since prior new type of chronic therapy (e.g., different category of&#xD;
             vasodilator, diuretic, digoxin) for pulmonary hypertension, except anticoagulants&#xD;
&#xD;
          -  At least 1 week since discontinuation of prior pulmonary hypertension medication,&#xD;
             except anticoagulants&#xD;
&#xD;
          -  At least 30 days since prior participation in an investigational drug study&#xD;
&#xD;
          -  No other concurrent investigational drug&#xD;
&#xD;
          -  No concurrent chronic intravenous or inhaled medications (except oxygen)&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No portal hypertension&#xD;
&#xD;
          -  No left sided heart disease as defined by: Pulmonary capillary wedge pressure or left&#xD;
             ventricular end diastolic pressure greater than 15 mm Hg OR LVEF less than 40% by MUGA&#xD;
             or angiography OR LV shortening fraction less than 22% by echocardiography OR&#xD;
             Symptomatic coronary disease (demonstrable ischemia)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Mentally and physically capable of using an infusion pump&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other disease associated with pulmonary hypertension (sickle cell anemia,&#xD;
             schistosomiasis)&#xD;
&#xD;
          -  No musculoskeletal disorder (arthritis, artificial leg, etc.) or any disease limiting&#xD;
             ambulation, or connected to a nonportable machine&#xD;
&#xD;
          -  No concurrent physiological condition contraindicating use of UT-15&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Walker Crow</last_name>
    <role>Study Chair</role>
    <affiliation>United Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian-St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Therapeutics Corporation</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 1999</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>hypertensive disorder</keyword>
  <keyword>primary pulmonary hypertension</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

